NCT05308446 2026-04-13
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
251 trialsNCT05745857 2026-04-13
SLURP
University Medical Center Groningen
Phase 2 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT07506109 2026-04-07
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06369259 2026-04-01
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07474727 2026-03-16
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2 Not yet recruiting
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03365882 2026-02-10
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
Phase 2 Completed
NCT03693807 2026-02-06
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00556413 2026-02-05
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Completed
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT07381764 2026-02-02
ROMANCE - GOIM
Gruppo Oncologico Italia Meridionale
Phase 2 Not yet recruiting
NCT04229459 2026-01-14
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Rabin Medical Center
Phase 2 Active not recruiting
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT06578559 2026-01-05
BRICKET
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT06540326 2025-12-22
Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05959356 2025-12-17
CEIL
Sun Yat-sen University
Phase 2 Recruiting
NCT07253896 2025-11-28
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT05510895 2025-10-01
NeoBRAF
AIO-Studien-gGmbH
Phase 2 Completed
NCT05104567 2025-09-24
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
Phase 2 Completed
NCT07183865 2025-09-19
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
Fudan University
Phase 2 Recruiting
NCT05694936 2025-09-18
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Phase 2 Recruiting
NCT05706779 2025-09-02
NEORAF
Federation Francophone de Cancerologie Digestive
Phase 2 Recruiting
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT03493048 2025-08-03
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05619172 2025-07-24
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
Phase 2 Terminated
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04554836 2025-06-08
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp
Phase 2 Completed
NCT00324415 2025-05-30
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
AIDS Malignancy Consortium
Phase 2 Completed
NCT05312398 2025-05-25
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
Phase 2 Active not recruiting
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT06908031 2025-05-14
CRIT
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Recruiting
NCT04853043 2025-05-06
APK Mutant
University of Utah
Phase 2 Terminated
NCT05004350 2025-04-15
NAUTICALCRC
Pierre Fabre Medicament
Phase 2 Completed
NCT06928584 2025-04-15
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT06763029 2025-02-27
VICPROIRI
Fudan University
Phase 2 Recruiting
NCT06640166 2025-02-12
ECLYPse
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Recruiting
NCT05167409 2025-01-13
A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT04513951 2025-01-09
AVETRIC
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT06411600 2024-11-08
BRAVE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT03874026 2024-11-07
CIFRA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT03164655 2024-10-01
SULTAN
UNICANCER
Phase 2 Completed
NCT05628038 2024-10-01
TORCH-R
Fudan University
Phase 2 Recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT06590259 2024-09-19
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
Shanghai 6th People's Hospital
Phase 2 Recruiting
NCT06603376 2024-09-19
Irinotecan Hydrochloride Liposome Injection (â…¡) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer
Shanghai Changzheng Hospital
Phase 2 Recruiting
NCT06575127 2024-08-28
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
Phase 2 Recruiting
NCT06547203 2024-08-09
Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study
Sun Yat-sen University
Phase 2 Recruiting